InterCure (INCR) Competitors $1.55 -0.02 (-1.52%) Closing price 05/1/2025 03:58 PM EasternExtended Trading$1.48 -0.07 (-4.45%) As of 05/1/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INCR vs. AVIR, TERN, ACB, SLDB, ATXS, SLRN, CDTX, HUMA, DRUG, and LFCRShould you be buying InterCure stock or one of its competitors? The main competitors of InterCure include Atea Pharmaceuticals (AVIR), Terns Pharmaceuticals (TERN), Aurora Cannabis (ACB), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Acelyrin (SLRN), Cidara Therapeutics (CDTX), Humacyte (HUMA), Bright Minds Biosciences (DRUG), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. InterCure vs. Atea Pharmaceuticals Terns Pharmaceuticals Aurora Cannabis Solid Biosciences Astria Therapeutics Acelyrin Cidara Therapeutics Humacyte Bright Minds Biosciences Lifecore Biomedical InterCure (NASDAQ:INCR) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, community ranking, dividends, profitability, analyst recommendations, institutional ownership and valuation. Does the media refer more to INCR or AVIR? In the previous week, Atea Pharmaceuticals had 3 more articles in the media than InterCure. MarketBeat recorded 5 mentions for Atea Pharmaceuticals and 2 mentions for InterCure. InterCure's average media sentiment score of 1.44 beat Atea Pharmaceuticals' score of 1.31 indicating that InterCure is being referred to more favorably in the media. Company Overall Sentiment InterCure Positive Atea Pharmaceuticals Positive Which has better earnings and valuation, INCR or AVIR? InterCure has higher revenue and earnings than Atea Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInterCure$272.67M0.26-$16.83MN/AN/AAtea PharmaceuticalsN/AN/A-$135.96M-$2.00-1.46 Is INCR or AVIR more profitable? InterCure's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets InterCureN/A N/A N/A Atea Pharmaceuticals N/A -34.90%-32.38% Do insiders and institutionals hold more shares of INCR or AVIR? 8.3% of InterCure shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 0.2% of InterCure shares are owned by company insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, INCR or AVIR? InterCure has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Do analysts rate INCR or AVIR? Atea Pharmaceuticals has a consensus price target of $6.00, suggesting a potential upside of 105.83%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Atea Pharmaceuticals is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community prefer INCR or AVIR? Atea Pharmaceuticals received 16 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 47.50% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperformInterCureOutperform Votes3100.00% Underperform VotesNo VotesAtea PharmaceuticalsOutperform Votes1947.50% Underperform Votes2152.50% SummaryInterCure and Atea Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get InterCure News Delivered to You Automatically Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCR vs. The Competition Export to ExcelMetricInterCurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.87M$6.72B$5.49B$7.94BDividend YieldN/A3.05%5.11%4.23%P/E RatioN/A7.3722.5818.55Price / Sales0.26242.94397.25103.00Price / CashN/A65.8538.1834.62Price / Book0.576.486.704.26Net Income-$16.83M$143.68M$3.23B$248.39M7 Day Performance13.32%1.79%1.26%1.27%1 Month Performance12.27%6.68%3.75%3.85%1 Year Performance-47.47%-2.73%15.78%5.23% InterCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCRInterCure1.3051 of 5 stars$1.55-1.5%N/A-47.6%$70.64M$272.67M0.00350Upcoming EarningsShort Interest ↓News CoveragePositive NewsAVIRAtea Pharmaceuticals3.1554 of 5 stars$2.86-3.7%$6.00+109.8%-22.3%$244.60MN/A-1.3870TERNTerns Pharmaceuticals4.2757 of 5 stars$2.71+12.9%$18.38+578.0%-29.9%$236.58MN/A-2.3040Positive NewsACBAurora Cannabis0.6346 of 5 stars$4.20-5.4%N/A-35.5%$236.10M$320.81M84.021,340News CoverageSLDBSolid Biosciences3.9735 of 5 stars$3.03+18.8%$15.67+417.1%-61.7%$234.80M$8.09M-1.00100News CoverageHigh Trading VolumeATXSAstria Therapeutics2.5351 of 5 stars$4.11+1.7%$26.60+547.2%-45.7%$231.94MN/A-1.9730Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageSLRNAcelyrin2.9945 of 5 stars$2.28+3.6%$9.60+321.1%-39.3%$230.07MN/A-0.93135Positive NewsCDTXCidara Therapeutics4.2409 of 5 stars$20.68+6.4%$39.14+89.3%+84.2%$226.51M$1.28M-0.8190Upcoming EarningsAnalyst ForecastNews CoverageHUMAHumacyte2.6606 of 5 stars$1.45-13.7%$13.71+845.8%-68.0%$224.92M$1.57M-1.08150News CoverageDRUGBright Minds Biosciences3.318 of 5 stars$31.89-3.7%$84.33+164.5%+2,844.2%$224.63MN/A-187.58N/ANews CoveragePositive NewsLFCRLifecore Biomedical1.6378 of 5 stars$6.04-5.8%$8.00+32.5%+6.1%$223.63M$130.86M-10.79690 Related Companies and Tools Related Companies AVIR Competitors TERN Competitors ACB Competitors SLDB Competitors ATXS Competitors SLRN Competitors CDTX Competitors HUMA Competitors DRUG Competitors LFCR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCR) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InterCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
